---
figid: PMC7200761__41389_2020_228_Fig7_HTML
figlink: pmc/articles/PMC7200761/figure/Fig7/
number: F7
caption: One of the mechanisms by which loss of HAT1 drives acquired BRAFi resistance
  is via IGF1R-dependent activation of MAPK signaling pathway, and the pharmacological
  targeting of IGF1R or ERK1/2 restores the sensitivity of melanoma cells with reduced
  HAT1 expression levels to BRAFi.
pmcid: PMC7200761
papertitle: Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma
  cells by activating MAPK signaling via IGF1R.
reftext: Suresh Bugide, et al. Oncogenesis. 2020 May;9(5):44.
pmc_ranked_result_index: '30973'
pathway_score: 0.9454672
filename: 41389_2020_228_Fig7_HTML.jpg
figtitle: Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma
  cells by activating MAPK signaling via IGF1R
year: '2020'
organisms: Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7200761__41389_2020_228_Fig7_HTML.html
  '@type': Dataset
  description: One of the mechanisms by which loss of HAT1 drives acquired BRAFi resistance
    is via IGF1R-dependent activation of MAPK signaling pathway, and the pharmacological
    targeting of IGF1R or ERK1/2 restores the sensitivity of melanoma cells with reduced
    HAT1 expression levels to BRAFi.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - HAT1
  - MAPK3
  - MAPK1
  - MAPK14
  - MAPK8
  - MAPK11
  - MAPK13
  - MAPK12
  - MAPK9
  - MAPK10
  - IGF1R
  - Vemurafenib
  - Dabrafenib
  - Melanoma
genes:
- word: HAT1
  symbol: HAT1
  source: hgnc_symbol
  hgnc_symbol: HAT1
  entrez: '8520'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: IGF1R
  symbol: IGF1R
  source: hgnc_symbol
  hgnc_symbol: IGF1R
  entrez: '3480'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
chemicals:
- word: Vemurafenib
  source: MESH
  identifier: C551177
- word: Dabrafenib
  source: MESH
  identifier: C561627
diseases:
- word: Melanoma
  source: MESH
  identifier: D008545
figid_alias: PMC7200761__F7
redirect_from: /figures/PMC7200761__F7
figtype: Figure
---
